Artemisitene suppresses rheumatoid arthritis progression via modulating METTL3‐mediated N6‐methyladenosine modification of ICAM2 mRNA in fibroblast‐like synoviocytes

Abstract Background Rheumatoid arthritis (RA) is a chronic autoimmune disease. We previously revealed that the natural compound artemisitene (ATT) exhibits excellent broad anticancer activities without toxicity on normal tissues. Nevertheless, the effect of ATT on RA is undiscovered. Herein, we aim...

Full description

Bibliographic Details
Main Authors: Jian Chen, Xian Lin, Juan He, Dandan Liu, Lianhua He, Miaomiao Zhang, Huijie Luan, Yiping Hu, Cheng Tao, Qingwen Wang
Format: Article
Language:English
Published: Wiley 2022-12-01
Series:Clinical and Translational Medicine
Subjects:
Online Access:https://doi.org/10.1002/ctm2.1148
_version_ 1797944094321803264
author Jian Chen
Xian Lin
Juan He
Dandan Liu
Lianhua He
Miaomiao Zhang
Huijie Luan
Yiping Hu
Cheng Tao
Qingwen Wang
author_facet Jian Chen
Xian Lin
Juan He
Dandan Liu
Lianhua He
Miaomiao Zhang
Huijie Luan
Yiping Hu
Cheng Tao
Qingwen Wang
author_sort Jian Chen
collection DOAJ
description Abstract Background Rheumatoid arthritis (RA) is a chronic autoimmune disease. We previously revealed that the natural compound artemisitene (ATT) exhibits excellent broad anticancer activities without toxicity on normal tissues. Nevertheless, the effect of ATT on RA is undiscovered. Herein, we aim to study the effect and potential mechanism of ATT on RA management. Methods A collagen‐induced arthritis (CIA) mouse model was employed to confirm the anti‐RA potential of ATT. Cell Counting Kit‐8 (CCK‐8) and 5‐ethynyl‐2'‐deoxyuridine (EdU) assays, cell cycle and apoptosis analysis, immunofluorescence, migration and invasion assays, quantitative real‐time PCR (RT‐qPCR), Western blot, RNA‐sequencing (RNA‐seq) analysis, plasmid construction and lentivirus infection, and methylated RNA immunoprecipitation and chromatin immunoprecipitation assays, were carried out to confirm the effect and potential mechanism of ATT on RA management. Results ATT relieved CIA in mice. ATT inhibited proliferation and induced apoptosis of RA‐fibroblast‐like synoviocytes (FLSs). ATT restrained RA‐FLSs migration and invasion via suppressing epithelial–mesenchymal transition. RNA‐sequencing analysis and bioinformatics analysis identified intercellular adhesion molecule 2 (ICAM2) as a promoter of RA progression in RA‐FLSs. ATT inhibits RA progression by suppressing ICAM2/phosphoinositide 3‐kinase (PI3K)/protein kinase B (AKT)/p300 pathway in RA‐FLSs. Moreover, ATT inhibited methyltransferase‐like 3 (METTL3)‐mediated N6‐methyladenosine methylation of ICAM2 mRNA in RA‐FLSs. Interestingly, p300 directly facilitated METTL3 transcription, which could be restrained by ATT in RA‐FLSs. Importantly, METTL3, ICAM2 and p300 expressions in synovium tissues of RA patients were related to clinical characteristics and therapy response. Conclusions We provided strong evidence that ATT has therapeutic potential for RA management by suppressing proliferation, migration and invasion, in addition to inducing apoptosis of RA‐FLSs through modulating METTL3/ICAM2/PI3K/AKT/p300 feedback loop, supplying the fundamental basis for the clinical application of ATT in RA therapy. Moreover, METTL3, ICAM2 and p300 might serve as biomarkers for the therapy response of RA patients.
first_indexed 2024-04-10T20:34:11Z
format Article
id doaj.art-b8bf8362c25748d8bf67a1c5d42db9b7
institution Directory Open Access Journal
issn 2001-1326
language English
last_indexed 2024-04-10T20:34:11Z
publishDate 2022-12-01
publisher Wiley
record_format Article
series Clinical and Translational Medicine
spelling doaj.art-b8bf8362c25748d8bf67a1c5d42db9b72023-01-25T04:06:34ZengWileyClinical and Translational Medicine2001-13262022-12-011212n/an/a10.1002/ctm2.1148Artemisitene suppresses rheumatoid arthritis progression via modulating METTL3‐mediated N6‐methyladenosine modification of ICAM2 mRNA in fibroblast‐like synoviocytesJian Chen0Xian Lin1Juan He2Dandan Liu3Lianhua He4Miaomiao Zhang5Huijie Luan6Yiping Hu7Cheng Tao8Qingwen Wang9Department of Rheumatism and Immunology Peking University Shenzhen Hospital Shenzhen Guangdong ChinaDepartment of Rheumatism and Immunology Peking University Shenzhen Hospital Shenzhen Guangdong ChinaDepartment of Rheumatism and Immunology Peking University Shenzhen Hospital Shenzhen Guangdong ChinaSchool of Basic Medical Science Guangzhou University of Chinese Medicine Guangzhou Guangdong ChinaDepartment of Rheumatism and Immunology Peking University Shenzhen Hospital Shenzhen Guangdong ChinaDepartment of Rheumatism and Immunology Peking University Shenzhen Hospital Shenzhen Guangdong ChinaDepartment of Rheumatism and Immunology Peking University Shenzhen Hospital Shenzhen Guangdong ChinaDepartment of Rheumatism and Immunology Peking University Shenzhen Hospital Shenzhen Guangdong ChinaSchool of Pharmacy Guangdong Medical University Dongguan Guangdong ChinaDepartment of Rheumatism and Immunology Peking University Shenzhen Hospital Shenzhen Guangdong ChinaAbstract Background Rheumatoid arthritis (RA) is a chronic autoimmune disease. We previously revealed that the natural compound artemisitene (ATT) exhibits excellent broad anticancer activities without toxicity on normal tissues. Nevertheless, the effect of ATT on RA is undiscovered. Herein, we aim to study the effect and potential mechanism of ATT on RA management. Methods A collagen‐induced arthritis (CIA) mouse model was employed to confirm the anti‐RA potential of ATT. Cell Counting Kit‐8 (CCK‐8) and 5‐ethynyl‐2'‐deoxyuridine (EdU) assays, cell cycle and apoptosis analysis, immunofluorescence, migration and invasion assays, quantitative real‐time PCR (RT‐qPCR), Western blot, RNA‐sequencing (RNA‐seq) analysis, plasmid construction and lentivirus infection, and methylated RNA immunoprecipitation and chromatin immunoprecipitation assays, were carried out to confirm the effect and potential mechanism of ATT on RA management. Results ATT relieved CIA in mice. ATT inhibited proliferation and induced apoptosis of RA‐fibroblast‐like synoviocytes (FLSs). ATT restrained RA‐FLSs migration and invasion via suppressing epithelial–mesenchymal transition. RNA‐sequencing analysis and bioinformatics analysis identified intercellular adhesion molecule 2 (ICAM2) as a promoter of RA progression in RA‐FLSs. ATT inhibits RA progression by suppressing ICAM2/phosphoinositide 3‐kinase (PI3K)/protein kinase B (AKT)/p300 pathway in RA‐FLSs. Moreover, ATT inhibited methyltransferase‐like 3 (METTL3)‐mediated N6‐methyladenosine methylation of ICAM2 mRNA in RA‐FLSs. Interestingly, p300 directly facilitated METTL3 transcription, which could be restrained by ATT in RA‐FLSs. Importantly, METTL3, ICAM2 and p300 expressions in synovium tissues of RA patients were related to clinical characteristics and therapy response. Conclusions We provided strong evidence that ATT has therapeutic potential for RA management by suppressing proliferation, migration and invasion, in addition to inducing apoptosis of RA‐FLSs through modulating METTL3/ICAM2/PI3K/AKT/p300 feedback loop, supplying the fundamental basis for the clinical application of ATT in RA therapy. Moreover, METTL3, ICAM2 and p300 might serve as biomarkers for the therapy response of RA patients.https://doi.org/10.1002/ctm2.1148artemisitenefibroblast‐like synoviocytesICAM2METTL3rheumatoid arthritis
spellingShingle Jian Chen
Xian Lin
Juan He
Dandan Liu
Lianhua He
Miaomiao Zhang
Huijie Luan
Yiping Hu
Cheng Tao
Qingwen Wang
Artemisitene suppresses rheumatoid arthritis progression via modulating METTL3‐mediated N6‐methyladenosine modification of ICAM2 mRNA in fibroblast‐like synoviocytes
Clinical and Translational Medicine
artemisitene
fibroblast‐like synoviocytes
ICAM2
METTL3
rheumatoid arthritis
title Artemisitene suppresses rheumatoid arthritis progression via modulating METTL3‐mediated N6‐methyladenosine modification of ICAM2 mRNA in fibroblast‐like synoviocytes
title_full Artemisitene suppresses rheumatoid arthritis progression via modulating METTL3‐mediated N6‐methyladenosine modification of ICAM2 mRNA in fibroblast‐like synoviocytes
title_fullStr Artemisitene suppresses rheumatoid arthritis progression via modulating METTL3‐mediated N6‐methyladenosine modification of ICAM2 mRNA in fibroblast‐like synoviocytes
title_full_unstemmed Artemisitene suppresses rheumatoid arthritis progression via modulating METTL3‐mediated N6‐methyladenosine modification of ICAM2 mRNA in fibroblast‐like synoviocytes
title_short Artemisitene suppresses rheumatoid arthritis progression via modulating METTL3‐mediated N6‐methyladenosine modification of ICAM2 mRNA in fibroblast‐like synoviocytes
title_sort artemisitene suppresses rheumatoid arthritis progression via modulating mettl3 mediated n6 methyladenosine modification of icam2 mrna in fibroblast like synoviocytes
topic artemisitene
fibroblast‐like synoviocytes
ICAM2
METTL3
rheumatoid arthritis
url https://doi.org/10.1002/ctm2.1148
work_keys_str_mv AT jianchen artemisitenesuppressesrheumatoidarthritisprogressionviamodulatingmettl3mediatedn6methyladenosinemodificationoficam2mrnainfibroblastlikesynoviocytes
AT xianlin artemisitenesuppressesrheumatoidarthritisprogressionviamodulatingmettl3mediatedn6methyladenosinemodificationoficam2mrnainfibroblastlikesynoviocytes
AT juanhe artemisitenesuppressesrheumatoidarthritisprogressionviamodulatingmettl3mediatedn6methyladenosinemodificationoficam2mrnainfibroblastlikesynoviocytes
AT dandanliu artemisitenesuppressesrheumatoidarthritisprogressionviamodulatingmettl3mediatedn6methyladenosinemodificationoficam2mrnainfibroblastlikesynoviocytes
AT lianhuahe artemisitenesuppressesrheumatoidarthritisprogressionviamodulatingmettl3mediatedn6methyladenosinemodificationoficam2mrnainfibroblastlikesynoviocytes
AT miaomiaozhang artemisitenesuppressesrheumatoidarthritisprogressionviamodulatingmettl3mediatedn6methyladenosinemodificationoficam2mrnainfibroblastlikesynoviocytes
AT huijieluan artemisitenesuppressesrheumatoidarthritisprogressionviamodulatingmettl3mediatedn6methyladenosinemodificationoficam2mrnainfibroblastlikesynoviocytes
AT yipinghu artemisitenesuppressesrheumatoidarthritisprogressionviamodulatingmettl3mediatedn6methyladenosinemodificationoficam2mrnainfibroblastlikesynoviocytes
AT chengtao artemisitenesuppressesrheumatoidarthritisprogressionviamodulatingmettl3mediatedn6methyladenosinemodificationoficam2mrnainfibroblastlikesynoviocytes
AT qingwenwang artemisitenesuppressesrheumatoidarthritisprogressionviamodulatingmettl3mediatedn6methyladenosinemodificationoficam2mrnainfibroblastlikesynoviocytes